Dialysis-Related Amyloidosis Treatment Act of 2025
Summary
HB4055, titled the Dialysis-Related Amyloidosis Treatment Act of 2025, would amend Medicare rules to expressly cover and pay for certain treatments for dialysis-related amyloidosis. The bill adds these treatments to the list of Medicare-covered services under Title XVIII of the Social Security Act and defines them as FDA-approved items or services furnished in a dialysis facility, along with necessary adjunct supplies and services.
The bill also specifies how Medicare would pay for these services. It excludes dialysis-related amyloidosis treatments from the bundled renal dialysis payment system and requires separate payment at 100 percent of reasonable charges. In effect, the legislation would create a distinct Medicare payment pathway for this condition rather than treating it as part of standard dialysis reimbursement.
If enacted, the bill would amend multiple sections of the Social Security Act governing Medicare coverage and payment, including provisions related to covered services, renal dialysis services, and prospective payment rules. The practical impact would be to require Medicare to reimburse qualifying dialysis facilities separately for FDA-approved dialysis-related amyloidosis treatments, potentially improving access for affected beneficiaries and providers.
The available legislative history shows no recorded votes or committee debate, so there is no documented opposition or support in the provided materials. The bill was simply introduced and referred to the House Committees on Energy and Commerce and Ways and Means, suggesting it is in an early stage of consideration. As a result, the overall sentiment cannot be measured from floor action, but the text indicates a targeted, technical Medicare coverage expansion for a specific patient population.
Impact
The bill would amend the Social Security Act to add dialysis-related amyloidosis treatments as a covered Medicare service and to require separate reimbursement outside the renal dialysis bundled payment system. It would affect Medicare beneficiaries with this condition, dialysis facilities, and Medicare payment administration by creating a new statutory payment category for FDA-approved treatments and related necessary supplies or services.
Sentiment
There is no recorded committee transcript or vote history in the provided materials, so no formal sentiment can be inferred from legislative debate or roll call action. Based on the bill text alone, the measure appears narrowly tailored and technical, aimed at expanding Medicare coverage for a specific complication of long-term dialysis rather than advancing a broader policy change.
Contention
No specific points of contention are documented in the provided record. Potential areas of debate, if the bill advances, would likely include whether the condition warrants a separate Medicare payment category, the cost implications of paying 100 percent of reasonable charges, and whether the FDA-approval and dialysis-facility limitations are sufficiently precise. At present, however, no member positions or objections are available.
Relating to Medicaid coverage and reimbursement for emergency outpatient dialysis treatment provided to certain individuals with end stage renal disease.
Relating to Medicaid coverage and reimbursement for emergency outpatient dialysis treatment provided to certain individuals with end stage renal disease.